Cancer-associated fibroblasts: A multifaceted driver of breast cancer progression

Cancer Letters

Volumn 361, Issue 2, 2015, Pages 155-163

  Luo, Haojun ^a   Tu, Gang ^a   Liu, Zhimin ^a   Liu, Manran ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Breast carcinoma; Cancer associated fibroblasts (CAFs); Progression; Tumor microenvironment

Indexed keywords

BREAST CANCER; BREAST CARCINOGENESIS; CANCER ASSOCIATED FIBROBLAST; CANCER GROWTH; CANCER RESISTANCE; CELL ASSAY; CELL FUNCTION; CELL INTERACTION; CELL INVASION; CELL LEVEL; CELL MIGRATION; CELL PROLIFERATION; DISEASE ACTIVITY; DISEASE ASSOCIATION; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; GROWTH RATE; HUMAN; LYMPHANGIOGENESIS; METASTASIS; MOLECULAR DYNAMICS; MOLECULAR MODEL; MOLECULAR PATHOLOGY; NONHUMAN; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; SHORT SURVEY; SYNDROME DELINEATION; TARGET CELL DESTRUCTION; TUMOR INVASION; TUMOR MICROENVIRONMENT; BREAST TUMOR; DISEASE COURSE; FEMALE; PATHOLOGY; PHYSIOLOGY; SURVIVAL;

BREAST NEOPLASMS; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; FIBROBLASTS; HUMANS; SURVIVAL ANALYSIS; TUMOR MICROENVIRONMENT;

EID: 84926132190     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.02.018     Document Type: Review

References (155)

1. Marx J. Cancer biology. All in the stroma: cancer's Cosa Nostra. Science 2008, 320:38-41.
2. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
3. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
4. Kessenbrock K., Plaks V., Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141:52-67.
5. Langley R.R., Fidler I.J. The seed and soil hypothesis revisited - the role of tumor-stroma interactions in metastasis to different organs. Int. J. Cancer 2011, 128:2527-2535.
6. Conklin M.W., Keely P.J. Why the stroma matters in breast cancer: insights into breast cancer patient outcomes through the examination of stromal biomarkers. Cell Adh. Migr 2012, 6:249-260.
7. Lu P., Weaver V.M., Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J. Cell Biol 2012, 196:395-406.
8. Mao Y., Keller E.T., Garfield D.H., Shen K., Wang J. Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev 2012, 32:303-315.
9. Swartz M.A., Iida N., Roberts E.W., Sangaletti S., Wong M.H., Yull F.E., et al. Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res 2012, 72:2473-2480.
10. Fleming J.M., Miller T.C., Quinones M., Xiao Z., Xu X., Meyer M.J., et al. The normal breast microenvironment of premenopausal women differentially influences the behavior of breast cancer cells in vitro and in vivo. BMC Med 2010, 8:27.
11. Cichon M.A., Degnim A.C., Visscher D.W., Radisky D.C. Microenvironmental influences that drive progression from benign breast disease to invasive breast cancer. J. Mammary Gland Biol. Neoplasia 2010, 15:389-397.
12. Hu M., Yao J., Carroll D.K., Weremowicz S., Chen H., Carrasco D., et al. Regulation of in situ to invasive breast carcinoma transition. Cancer Cell 2008, 13:394-406.
13. Qian N., Ueno T., Kawaguchi-Sakita N., Kawashima M., Yoshida N., Mikami Y., et al. Prognostic significance of tumor/stromal caveolin-1 expression in breast cancer patients. Cancer Sci 2011, 102:1590-1596.
14. de Kruijf E.M., van Nes J.G., van de Velde C.J., Putter H., Smit V.T., Liefers G.J., et al. Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. Breast Cancer Res. Treat 2011, 125:687-696.
15. Sappino A.P., Skalli O., Jackson B., Schurch W., Gabbiani G. Smooth-muscle differentiation in stromal cells of malignant and non-malignant breast tissues. Int. J. Cancer 1988, 41:707-712.
16. Kalluri R., Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer 2006, 6:392-401.
17. Orimo A., Gupta P.B., Sgroi D.C., Arenzana-Seisdedos F., Delaunay T., Naeem R., et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121:335-348.
18. Raz Y., Erez N. An inflammatory vicious cycle: fibroblasts and immune cell recruitment in cancer. Exp. Cell Res 2013, 319:1596-1603.
19. Pavlides S., Vera I., Gandara R., Sneddon S., Pestell R.G., Mercier I., et al. Warburg meets autophagy: cancer-associated fibroblasts accelerate tumor growth and metastasis via oxidative stress, mitophagy, and aerobic glycolysis. Antioxid. Redox Signal 2012, 16:1264-1284.
20. Cirri P., Chiarugi P. Cancer associated fibroblasts: the dark side of the coin. Am. J. Cancer Res 2011, 1:482-497.
21. Kojima Y., Acar A., Eaton E.N., Mellody K.T., Scheel C., Ben-Porath I., et al. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:20009-20014.
22. Zeisberg E.M., Potenta S., Xie L., Zeisberg M., Kalluri R. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res 2007, 67:10123-10128.
23. Polanska U.M., Acar A., Orimo A. Experimental generation of carcinoma-associated fibroblasts (CAFs) from human mammary fibroblasts. J. Vis. Exp 2011, 56:e3201.
24. Trimboli A.J., Cantemir-Stone C.Z., Li F., Wallace J.A., Merchant A., Creasap N., et al. Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature 2009, 461:1084-1091.
25. Tchou J., Conejo-Garcia J. Targeting the tumor stroma as a novel treatment strategy for breast cancer: shifting from the neoplastic cell-centric to a stroma-centric paradigm. Adv. Pharmacol 2012, 65:45-61.
26. Zhang J., Liu J. Tumor stroma as targets for cancer therapy. Pharmacol. Ther 2013, 137:200-215.
27. Elenbaas B., Weinberg R.A. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp. Cell Res 2001, 264:169-184.
28. Strutz F. The fibroblast - a (trans-) differentiated cell?. Nephrol. Dial. Transplant 1995, 10:1504-1506.
29. Wintzell M., Hjerpe E., Avall-Lundqvist E., Shoshan M. Protein markers of cancer-associated fibroblasts and tumor-initiating cells reveal subpopulations in freshly isolated ovarian cancer ascites. BMC Cancer 2012, 12:359.
30. Witkiewicz A.K., Dasgupta A., Sotgia F., Mercier I., Pestell R.G., Sabel M., et al. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am. J. Pathol 2009, 174:2023-2034.
31. Witkiewicz A.K., Dasgupta A., Sammons S., Er O., Potoczek M.B., Guiles F., et al. Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers. Cancer Biol. Ther 2010, 10:135-143.
32. El-Gendi S.M., Mostafa M.F., El-Gendi A.M. Stromal caveolin-1 expression in breast carcinoma. Correlation with early tumor recurrence and clinical outcome. Pathol. Oncol. Res 2012, 18:459-469.
33. Sloan E.K., Ciocca D.R., Pouliot N., Natoli A., Restall C., Henderson M.A., et al. Stromal cell expression of caveolin-1 predicts outcome in breast cancer. Am. J. Pathol 2009, 174:2035-2043.
34. Mercier I., Casimiro M.C., Wang C., Rosenberg A.L., Quong J., Minkeu A., et al. Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: Implications for the response to hormonal therapy. Cancer Biol. Ther 2008, 7:1212-1225.
35. Ren M., Liu F., Zhu Y., Li Y., Lang R., Fan Y., et al. Absence of caveolin-1 expression in carcinoma-associated fibroblasts of invasive micropapillary carcinoma of the breast predicts poor patient outcome. Virchows Arch 2014, 465:291-298.
36. Yamashita M., Ogawa T., Zhang X., Hanamura N., Kashikura Y., Takamura M., et al. Role of stromal myofibroblasts in invasive breast cancer: stromal expression of alpha-smooth muscle actin correlates with worse clinical outcome. Breast Cancer 2012, 19:170-176.
37. Surowiak P., Murawa D., Materna V., Maciejczyk A., Pudelko M., Ciesla S., et al. Occurrence of stromal myofibroblasts in the invasive ductal breast cancer tissue is an unfavourable prognostic factor. Anticancer Res 2007, 27:2917-2924.
38. Surowiak P., Suchocki S., Gyorffy B., Gansukh T., Wojnar A., Maciejczyk A., et al. Stromal myofibroblasts in breast cancer: relations between their occurrence, tumor grade and expression of some tumour markers. Folia Histochem. Cytobiol 2006, 44:111-116.
39. Dabiri S., Talebi A., Shahryari J., Meymandi M.S., Safizadeh H. Distribution of myofibroblast cells and microvessels around invasive ductal carcinoma of the breast and comparing with the adjacent range of their normal-to-DCIS zones. Arch. Iran. Med 2013, 16:93-99.
40. Yazhou C., Wenlv S., Weidong Z., Licun W. Clinicopathological significance of stromal myofibroblasts in invasive ductal carcinoma of the breast. Tumour Biol 2004, 25:290-295.
41. Hasebe T., Okada N., Tamura N., Houjoh T., Akashi-Tanaka S., Tsuda H., et al. p53 expression in tumor stromal fibroblasts is associated with the outcome of patients with invasive ductal carcinoma of the breast. Cancer Sci 2009, 100:2101-2108.
42. Hasebe T., Tamura N., Okada N., Hojo T., Akashi-Tanaka S., Shimizu C., et al. p53 expression in tumor-stromal fibroblasts is closely associated with the nodal metastasis and outcome of patients with invasive ductal carcinoma who received neoadjuvant therapy. Hum. Pathol 2010, 41:262-270.
43. Schoppmann S.F., Berghoff A., Dinhof C., Jakesz R., Gnant M., Dubsky P., et al. Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer. Breast Cancer Res. Treat 2012, 134:237-244.
44. Pula B., Jethon A., Piotrowska A., Gomulkiewicz A., Owczarek T., Calik J., et al. Podoplanin expression by cancer-associated fibroblasts predicts poor outcome in invasive ductal breast carcinoma. Histopathology 2011, 59:1249-1260.
45. Pula B., Wojnar A., Werynska B., Ambicka A., Kruczak A., Witkiewicz W., et al. Impact of different tumour stroma assessment methods regarding podoplanin expression on clinical outcome in patients with invasive ductal breast carcinoma. Anticancer Res 2013, 33:1447-1455.
46. Niemiec J.A., Adamczyk A., Ambicka A., Mucha-Malecka A., Wysocki W.M., Rys J. Triple-negative, basal marker-expressing, and high-grade breast carcinomas are characterized by high lymphatic vessel density and the expression of podoplanin in stromal fibroblasts. Appl. Immunohistochem. Mol. Morphol 2013, 22:10-16.
47. Puri V., Jain M., Thomas S. Stromal expression of CD10 in invasive breast carcinoma and its correlation with ER, PR, HER2-neu, and Ki67. Int. J. Breast Cancer 2011, 2011:437957.
48. Kim H.S., Kim G.Y., Kim Y.W., Park Y.K., Song J.Y., Lim S.J. Stromal CD10 expression and relationship to the E-cadherin/beta-catenin complex in breast carcinoma. Histopathology 2010, 56:708-719.
49. Iwaya K., Ogawa H., Izumi M., Kuroda M., Mukai K. Stromal expression of CD10 in invasive breast carcinoma: a new predictor of clinical outcome. Virchows Arch 2002, 440:589-593.
50. Makretsov N.A., Hayes M., Carter B.A., Dabiri S., Gilks C.B., Huntsman D.G. Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade. Mod. Pathol 2007, 20:84-89.
51. Desmedt C., Majjaj S., Kheddoumi N., Singhal S.K., Haibe-Kains B., El Ouriaghli F., et al. Characterization and clinical evaluation of CD10+ stroma cells in the breast cancer microenvironment. Clin. Cancer Res 2012, 18:1004-1014.
52. Ariga N., Sato E., Ohuchi N., Nagura H., Ohtani H. Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast. Int. J. Cancer 2001, 95:67-72.
53. Ranogajec I., Jakic-Razumovic J., Puzovic V., Gabrilovac J. Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase N/CD13 in breast cancer patients. Med. Oncol 2012, 29:561-569.
54. Bostrom P., Soderstrom M., Vahlberg T., Soderstrom K.O., Roberts P.J., Carpen O., et al. MMP-1 expression has an independent prognostic value in breast cancer. BMC Cancer 2011, 11:348.
55. Gonzalez L.O., Gonzalez-Reyes S., Marin L., Gonzalez L., Gonzalez J.M., Lamelas M.L., et al. Comparative analysis and clinical value of the expression of metalloproteases and their inhibitors by intratumour stromal mononuclear inflammatory cells and those at the invasive front of breast carcinomas. Histopathology 2010, 57:862-876.
56. Del Casar J.M., Gonzalez L.O., Alvarez E., Junquera S., Marin L., Gonzalez L., et al. Comparative analysis and clinical value of the expression of metalloproteases and their inhibitors by intratumor stromal fibroblasts and those at the invasive front of breast carcinomas. Breast Cancer Res. Treat 2009, 116:39-52.
57. Tokes A.M., Kulka J. [Tenascin-C expression in human breast tumors]. Orv. Hetil 2003, 144:1901-1907.
58. Ishihara A., Yoshida T., Tamaki H., Sakakura T. Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. Clin. Cancer Res 1995, 1:1035-1041.
59. Ioachim E., Charchanti A., Briasoulis E., Karavasilis V., Tsanou H., Arvanitis D.L., et al. Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur. J. Cancer 2002, 38:2362-2370.
60. Iskaros B.F., Hu X., Sparano J.A., Fineberg S.A. Tenascin pattern of expression and established prognostic factors in invasive breast carcinoma. J. Surg. Oncol 1998, 68:107-112.
61. Weigel M.T., Banerjee S., Arnedos M., Salter J., A'Hern R., Dowsett M., et al. Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer. Ann. Oncol 2012, 24:126-133.
62. Weigel M.T., Banerjee S., Arnedos M., Salter J., A'Hern R., Dowsett M., et al. Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer. Ann. Oncol 2013, 24:126-133.
63. Sotgia F., Del Galdo F., Casimiro M.C., Bonuccelli G., Mercier I., Whitaker-Menezes D., et al. Caveolin-1-/- null mammary stromal fibroblasts share characteristics with human breast cancer-associated fibroblasts. Am. J. Pathol 2009, 174:746-761.
64. Moorman A.M., Vink R., Heijmans H.J., van der Palen J., Kouwenhoven E.A. The prognostic value of tumour-stroma ratio in triple-negative breast cancer. Eur. J. Surg.Oncol 2012, 38:307-313.
65. Ahn S., Cho J., Sung J., Lee J.E., Nam S.J., Kim K.M., et al. The prognostic significance of tumor-associated stroma in invasive breast carcinoma. Tumour Biol 2012, 33:1573-1580.
66. Walker R.A. The complexities of breast cancer desmoplasia. Breast Cancer Res 2001, 3:143-145.
67. Paulsson J., Micke P. Prognostic relevance of cancer-associated fibroblasts in human cancer. Semin. Cancer Biol 2014, 25:61-68.
68. Dumont N., Liu B., Defilippis R.A., Chang H., Rabban J.T., Karnezis A.N., et al. Breast fibroblasts modulate early dissemination, tumorigenesis, and metastasis through alteration of extracellular matrix characteristics. Neoplasia 2013, 15:249-262.
69. Nguyen D.H., Oketch-Rabah H.A., Illa-Bochaca I., Geyer F.C., Reis-Filho J.S., Mao J.H., et al. Radiation acts on the microenvironment to affect breast carcinogenesis by distinct mechanisms that decrease cancer latency and affect tumor type. Cancer Cell 2011, 19:640-651.
70. Hill R., Song Y., Cardiff R.D., Van Dyke T. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 2005, 123:1001-1011.
71. Scherz-Shouval R., Santagata S., Mendillo M.L., Sholl L.M., Ben-Aharon I., Beck A.H., et al. The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy. Cell 2014, 158:564-578.
72. Shekhar M.P., Werdell J., Santner S.J., Pauley R.J., Tait L. Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. Cancer Res 2001, 61:1320-1326.
73. Sadlonova A., Novak Z., Johnson M.R., Bowe D.B., Gault S.R., Page G.P., et al. Breast fibroblasts modulate epithelial cell proliferation in three-dimensional in vitro co-culture. Breast Cancer Res 2005, 7:R46-R59.
74. Holliday D.L., Brouilette K.T., Markert A., Gordon L.A., Jones J.L. Novel multicellular organotypic models of normal and malignant breast: tools for dissecting the role of the microenvironment in breast cancer progression. Breast Cancer Res 2009, 11:R3.
75. Martinez-Outschoorn U.E., Balliet R.M., Rivadeneira D.B., Chiavarina B., Pavlides S., Wang C., et al. Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: a new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle 2010, 9:3256-3276.
76. Romer A.M., Luhr I., Klein A., Friedl A., Sebens S., Rosel F., et al. Normal mammary fibroblasts induce reversion of the malignant phenotype in human primary breast cancer. Anticancer Res 2013, 33:1525-1536.
77. Guido C., Whitaker-Menezes D., Capparelli C., Balliet R., Lin Z., Pestell R.G., et al. Metabolic reprogramming of cancer-associated fibroblasts by TGF-beta drives tumor growth: Connecting TGF-beta signaling with "Warburg-like" cancer metabolism and L-lactate production. Cell Cycle 2012, 11:3019-3035.
78. Barone I., Catalano S., Gelsomino L., Marsico S., Giordano C., Panza S., et al. Leptin mediates tumor-stromal interactions that promote the invasive growth of breast cancer cells. Cancer Res 2012, 72:1416-1427.
79. Weber C.E., Kothari A.N., Wai P.Y., Li N.Y., Driver J., Zapf M.A., et al. Osteopontin mediates an MZF1-TGF-beta1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer. Oncogene 2014.
80. Tyan S.W., Kuo W.H., Huang C.K., Pan C.C., Shew J.Y., Chang K.J., et al. Breast cancer cells induce cancer-associated fibroblasts to secrete hepatocyte growth factor to enhance breast tumorigenesis. PLoS ONE 2011, 6:e15313.
81. Martens J.W., Sieuwerts A.M., Bolt-deVries J., Bosma P.T., Swiggers S.J., Klijn J.G., et al. Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progression. Thromb. Haemost 2003, 89:393-404.
82. Palmieri C., Roberts-Clark D., Assadi-Sabet A., Coope R.C., O'Hare M., Sunters A., et al. Fibroblast growth factor 7, secreted by breast fibroblasts, is an interleukin-1beta-induced paracrine growth factor for human breast cells. J. Endocrinol 2003, 177:65-81.
83. Fleming J.M., Leibowitz B.J., Kerr D.E., Cohick W.S. IGF-I differentially regulates IGF-binding protein expression in primary mammary fibroblasts and epithelial cells. J. Endocrinol 2005, 186:165-178.
84. Locatelli A., Lofgren K.A., Daniel A.R., Castro N.E., Lange C.A. Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression. Horm. Cancer 2012, 3:14-25.
85. Cabioglu N., Summy J., Miller C., Parikh N.U., Sahin A.A., Tuzlali S., et al. CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res 2005, 65:6493-6497.
86. Clarke M.J. WITHDRAWN: tamoxifen for early breast cancer. Cochrane Database Syst. Rev 2008, (4). CD000486.
87. Sasano H., Miki Y., Shibuya R., Suzuki T. Aromatase and in situ estrogen production in DCIS (ductal carcinoma in situ) of human breast. J. Steroid Biochem. Mol. Biol 2010, 118:242-245.
88. Miki Y., Suzuki T., Tazawa C., Yamaguchi Y., Kitada K., Honma S., et al. Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells. Cancer Res 2007, 67:3945-3954.
89. Yamaguchi Y., Takei H., Suemasu K., Kobayashi Y., Kurosumi M., Harada N., et al. Tumor-stromal interaction through the estrogen-signaling pathway in human breast cancer. Cancer Res 2005, 65:4653-4662.
90. Suda T., Oba H., Takei H., Kurosumi M., Hayashi S., Yamaguchi Y. ER-activating ability of breast cancer stromal fibroblasts is regulated independently of alteration of TP53 and PTEN tumor suppressor genes. Biochem. Biophys. Res. Commun 2012, 428:259-263.
91. Katz E., Dubois-Marshall S., Sims A.H., Gautier P., Caldwell H., Meehan R.R., et al. An in vitro model that recapitulates the epithelial to mesenchymal transition (EMT) in human breast cancer. PLoS ONE 2011, 6:e17083.
92. Gos M., Miloszewska J., Przybyszewska M. [Epithelial-mesenchymal transition in cancer progression]. Postepy Biochem 2009, 55:121-128.
93. Giannoni E., Parri M., Chiarugi P. EMT and oxidative stress: a bidirectional interplay affecting tumor malignancy. Antioxid. Redox Signal 2012, 16:1248-1263.
94. Gao M.Q., Kim B.G., Kang S., Choi Y.P., Park H., Kang K.S., et al. Stromal fibroblasts from the interface zone of human breast carcinomas induce an epithelial-mesenchymal transition-like state in breast cancer cells in vitro. J. Cell Sci 2010, 123:3507-3514.
95. Soon P.S., Kim E., Pon C.K., Gill A.J., Moore K., Spillane A.J., et al. Breast cancer-associated fibroblasts induce epithelial-to-mesenchymal transition in breast cancer cells. Endocr. Relat. Cancer 2013, 20:1-12.
96. Lee K.W., Yeo S.Y., Sung C.O., Kim S.H. Twist1 is a key regulator of cancer-associated fibroblasts. Cancer Res 2015, 75:73-85.
97. Al-Ansari M.M., Hendrayani S.F., Shehata A.I., Aboussekhra A. p16(INK4A) represses the paracrine tumor-promoting effects of breast stromal fibroblasts. Oncogene 2013, 32:2356-2364.
98. Giannoni E., Bianchini F., Calorini L., Chiarugi P. Cancer associated fibroblasts exploit reactive oxygen species through a proinflammatory signature leading to epithelial mesenchymal transition and stemness. Antioxid. Redox Signal 2011, 14:2361-2371.
99. de Herreros A.G., Peiro S., Nassour M., Savagner P. Snail family regulation and epithelial mesenchymal transitions in breast cancer progression. J. Mammary Gland Biol. Neoplasia 2010, 15:135-147.
100. Yu Y., Xiao C.H., Tan L.D., Wang Q.S., Li X.Q., Feng Y.M. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-beta signalling. Br. J. Cancer 2014, 110:724-732.
101. Mink S.R., Vashistha S., Zhang W., Hodge A., Agus D.B., Jain A. Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs. Mol. Cancer Res 2010, 8:809-820.
102. Madar S., Goldstein I., Rotter V. 'Cancer associated fibroblasts' - more than meets the eye. Trends Mol. Med 2013, 19:447-453.
103. Brentnall T.A. Arousal of cancer-associated stromal fibroblasts: palladin-activated fibroblasts promote tumor invasion. Cell Adh. Migr 2012, 6:488-494.
104. Hynes R.O. The extracellular matrix: not just pretty fibrils. Science 2009, 326:1216-1219.
105. Roy R., Yang J., Moses M.A. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J. Clin. Oncol 2009, 27:5287-5297.
106. Przybylo J.A., Radisky D.C. Matrix metalloproteinase-induced epithelial-mesenchymal transition: tumor progression at Snail's pace. Int. J. Biochem. Cell Biol 2007, 39:1082-1088.
107. Lochter A., Galosy S., Muschler J., Freedman N., Werb Z., Bissell M.J. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J. Cell Biol 1997, 139:1861-1872.
108. Radisky D.C., Levy D.D., Littlepage L.E., Liu H., Nelson C.M., Fata J.E., et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 2005, 436:123-127.
109. Hu M., Peluffo G., Chen H., Gelman R., Schnitt S., Polyak K. Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:3372-3377.
110. Karagiannis G.S., Poutahidis T., Erdman S.E., Kirsch R., Riddell R.H., Diamandis E.P. Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue. Mol. Cancer Res 2012, 10:1403-1418.
111. Jain R.K., Martin J.D., Stylianopoulos T. The role of mechanical forces in tumor growth and therapy. Annu. Rev. Biomed. Eng 2014, 16:321-346.
112. Schedin P., Keely P.J. Mammary gland ECM remodeling, stiffness, and mechanosignaling in normal development and tumor progression. Cold Spring Harb. Perspect. Biol 2011, 3:a003228.
113. Stanisavljevic J., Loubat-Casanovas J., Herrera M., Luque T., Pena R., Lluch A., et al. Snail1-expressing fibroblasts in the tumor microenvironment display mechanical properties that support metastasis. Cancer Res 2015, 75:284-295.
114. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
115. Duda D.G., Duyverman A.M., Kohno M., Snuderl M., Steller E.J., Fukumura D., et al. Malignant cells facilitate lung metastasis by bringing their own soil. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:21677-21682.
116. Gonzalez-Zubeldia I., Dotor J., Redrado M., Bleau A.M., Manrique I., de Aberasturi A.L., et al. Co-migration of colon cancer cells and CAFs induced by TGFbeta enhances liver metastasis. Cell Tissue Res 2015, 359:829-839.
117. Choi Y.P., Lee J.H., Gao M.Q., Kim B.G., Kang S., Kim S.H., et al. Cancer-associated fibroblast promote transmigration through endothelial brain cells in three-dimensional in vitro models. Int. J. Cancer 2014, 135:2024-2033.
118. Kang N., Shah V.H., Urrutia R. Membrane-to-nucleus signals and epigenetic mechanisms for myofibroblastic activation and desmoplastic stroma: potential therapeutic targets for liver metastasis?. Mol. Cancer Res 2014.
119. Peinado H., Lavotshkin S., Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin. Cancer Biol 2011, 21:139-146.
120. Amornsupak K., Insawang T., Thuwajit P., O-Charoenrat P., Eccles S.A., Thuwajit C. Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells. BMC Cancer 2014, 14:955.
121. Mueller K.L., Madden J.M., Zoratti G.L., Kuperwasser C., List K., Boerner J.L. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met. Breast Cancer Res 2012, 14:R104.
122. Sun X., Mao Y., Wang J., Zu L., Hao M., Cheng G., et al. IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer. Oncogene 2014, 33:4450.
123. Loeffler M., Kruger J.A., Niethammer A.G., Reisfeld R.A. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J. Clin. Invest 2006, 116:1955-1962.
124. Shekhar M.P., Santner S., Carolin K.A., Tait L. Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivity. Am. J. Pathol 2007, 170:1546-1560.
125. Pontiggia O., Sampayo R., Raffo D., Motter A., Xu R., Bissell M.J., et al. The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through beta1 integrin. Breast Cancer Res. Treat 2012, 133:459-471.
126. Martinez-Outschoorn U.E., Goldberg A., Lin Z., Ko Y.H., Flomenberg N., Wang C., et al. Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biol. Ther 2011, 12:924-938.
127. Martinez-Outschoorn U.E., Lin Z., Ko Y.H., Goldberg A.F., Flomenberg N., Wang C., et al. Understanding the metabolic basis of drug resistance: therapeutic induction of the Warburg effect kills cancer cells. Cell Cycle 2011, 10:2521-2528.
128. Raica M., Cimpean A.M., Ribatti D. Angiogenesis in pre-malignant conditions. Eur. J. Cancer 2009, 45:1924-1934.
129. Maeda T., Desouky J., Friedl A. Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis. Oncogene 2006, 25:1408-1412.
130. Wang J., Sun Y., Song W., Nor J.E., Wang C.Y., Taichman R.S. Diverse signaling pathways through the SDF-1/CXCR4 chemokine axis in prostate cancer cell lines leads to altered patterns of cytokine secretion and angiogenesis. Cell. Signal 2005, 17:1578-1592.
131. Baeriswyl V., Christofori G. The angiogenic switch in carcinogenesis. Semin. Cancer Biol 2009, 19:329-337.
132. Shimo T., Kubota S., Kondo S., Nakanishi T., Sasaki A., Mese H., et al. Connective tissue growth factor as a major angiogenic agent that is induced by hypoxia in a human breast cancer cell line. Cancer Lett 2001, 174:57-64.
133. Ran S., Volk L., Hall K., Flister M.J. Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology 2010, 17:229-251.
134. Pula B., Wojnar A., Witkiewicz W., Dziegiel P., Podhorska-Okolow M. Podoplanin expression in cancer-associated fibroblasts correlates with VEGF-C expression in cancer cells of invasive ductal breast carcinoma. Neoplasma 2013, 60:516-524.
135. Koyama H., Kobayashi N., Harada M., Takeoka M., Kawai Y., Sano K., et al. Significance of tumor-associated stroma in promotion of intratumoral lymphangiogenesis: pivotal role of a hyaluronan-rich tumor microenvironment. Am. J. Pathol 2008, 172:179-193.
136. Bjorndahl M., Cao R., Nissen L.J., Clasper S., Johnson L.A., Xue Y., et al. Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:15593-15598.
137. Cao R., Bjorndahl M.A., Gallego M.I., Chen S., Religa P., Hansen A.J., et al. Hepatocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action. Blood 2006, 107:3531-3536.
138. Matsuo M., Yamada S., Koizumi K., Sakurai H., Saiki I. Tumour-derived fibroblast growth factor-2 exerts lymphangiogenic effects through Akt/mTOR/p70S6kinase pathway in rat lymphatic endothelial cells. Eur. J. Cancer 2007, 43:1748-1754.
139. Gomes F.G., Nedel F., Alves A.M., Nor J.E., Tarquinio S.B. Tumor angiogenesis and lymphangiogenesis: tumor/endothelial crosstalk and cellular/microenvironmental signaling mechanisms. Life Sci 2013, 92:101-107.
140. Ozbek S., Balasubramanian P.G., Chiquet-Ehrismann R., Tucker R.P., Adams J.C. The evolution of extracellular matrix. Mol. Biol. Cell 2010, 21:4300-4305.
141. Yang N., Mosher R., Seo S., Beebe D., Friedl A. Syndecan-1 in breast cancer stroma fibroblasts regulates extracellular matrix fiber organization and carcinoma cell motility. Am. J. Pathol 2011, 178:325-335.
142. Colotta F., Allavena P., Sica A., Garlanda C., Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009, 30:1073-1081.
143. Galdiero M.R., Garlanda C., Jaillon S., Marone G., Mantovani A. Tumor associated macrophages and neutrophils in tumor progression. J. Cell. Physiol 2012, 228:1404-1412.
144. Ksiazkiewicz M., Gottfried E., Kreutz M., Mack M., Hofstaedter F., Kunz-Schughart L.A. Importance of CCL2-CCR2A/2B signaling for monocyte migration into spheroids of breast cancer-derived fibroblasts. Immunobiology 2010, 215:737-747.
145. Qian B.Z., Li J., Zhang H., Kitamura T., Zhang J., Campion L.R., et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011, 475:222-225.
146. Fang W.B., Jokar I., Chytil A., Moses H.L., Abel T., Cheng N. Loss of one Tgfbr2 allele in fibroblasts promotes metastasis in MMTV: polyoma middle T transgenic and transplant mouse models of mammary tumor progression. Clin. Exp. Metastasis 2011, 28:351-366.
147. Chomarat P., Banchereau J., Davoust J., Palucka A.K. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat. Immunol 2000, 1:510-514.
148. Liao D., Luo Y., Markowitz D., Xiang R., Reisfeld R.A. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS ONE 2009, 4:e7965.
149. Sharon Y., Raz Y., Cohen N., Ben-Shmuel A., Schwartz H., Geiger T., et al. Tumor-derived osteopontin reprograms normal mammary fibroblasts to promote inflammation and tumor growth in breast cancer. Cancer Res 2015.
150. Pavlides S., Whitaker-Menezes D., Castello-Cros R., Flomenberg N., Witkiewicz A.K., Frank P.G., et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 2009, 8:3984-4001.
151. Martinez-Outschoorn U.E., Pavlides S., Howell A., Pestell R.G., Tanowitz H.B., Sotgia F., et al. Stromal-epithelial metabolic coupling in cancer: integrating autophagy and metabolism in the tumor microenvironment. Int. J. Biochem. Cell Biol 2011, 43:1045-1051.
152. Martinez-Outschoorn U., Sotgia F., Lisanti M.P. Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function. Semin. Oncol 2014, 41:195-216.
153. Migneco G., Whitaker-Menezes D., Chiavarina B., Castello-Cros R., Pavlides S., Pestell R.G., et al. Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: evidence for stromal-epithelial metabolic coupling. Cell Cycle 2010, 9:2412-2422.
154. Sotgia F., Whitaker-Menezes D., Martinez-Outschoorn U.E., Flomenberg N., Birbe R.C., Witkiewicz A.K., et al. Mitochondrial metabolism in cancer metastasis: visualizing tumor cell mitochondria and the "reverse Warburg effect" in positive lymph node tissue. Cell Cycle 2012, 11:1445-1454.
155. Brennen W.N., Isaacs J.T., Denmeade S.R. Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol. Cancer Ther 2012, 11:257-266.